NSE · ALIVUS
Alivus Life Sciences Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹2,612 Cr with net profit ₹564 Cr — a 21.61% net margin, versus 20.06% the period before.
Shareholding
As of 2026-06-30
- Promoter74.87%
- Public12.41%
- FII5.54%
- DII7.18%
1,25,559 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.82× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Drug Manufacturers - Specialty & Generic · ranked #2 of 15 by market cap · medians across 14 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Astrazeneca Pharma India Ltd. | ₹17,151 Cr | 98.87 | 19.65 | 21.49% | 6.97% |
| Alivus Life Sciences Ltd.(this company) | ₹17,068 Cr | 27.45 | 5.13 | 16.94% | 23.28% |
| Akums Drugs & Pharmaceuticals Ltd. | ₹11,799 Cr | 38.64 | 3.56 | 7.7% | 6.48% |
| Procter & Gamble Health Limited | ₹9,006 Cr | 27.03 | 17.16 | 62.32% | 24.91% |
| Gujarat Themis Biosyn Ltd. | ₹5,598 Cr | 119.81 | 7.4 | — | 25.04% |
| Jagsonpal Pharmaceuticals Ltd. | ₹1,537 Cr | 32.68 | 5.56 | 15.6% | 15.47% |
| Bajaj HealthCare Limited | ₹1,122 Cr | 19.93 | 2.1 | 8.81% | 2.81% |
| Anuh Pharma Limited | ₹914 Cr | 20.68 | 2.6 | 11.65% | 5.67% |
| Amanta Healthcare Limited | ₹784 Cr | 51.08 | 3.57 | 7.46% | 5.04% |
| Bafna Pharmaceuticals Ltd. | ₹728 Cr | 93.5 | 7.31 | 11.54% | 5.46% |
AI analysis
AI-generated · google/gemini-2.5-flashAlivus Life Sciences Ltd. (formerly Glenmark Life Sciences Limited) was founded in 2001 and is based in Mumbai, India. It is a subsidiary of Nirma Limited. The company develops, manufactures, and markets active pharmaceutical ingredients (APIs) for various therapeutic areas across India, Japan, Europe, North and Latin America, and internationally. Alivus Life Sciences Ltd. also provides contract development and manufacturing services to multinational corporations and specialty companies.
Positives
- +The company maintains a strong profit margin of 22.12%.
- +Alivus Life Sciences Ltd. has a low debt-to-equity ratio of 0.01.
- +The Return on Capital Employed (ROCE) is 22.33%, indicating efficient use of capital.
- +Promoter shareholding is substantial at 74.87% as of June 2026.
- +The dividend yield is 44%, indicating a high payout to shareholders.
Negatives
- −Revenue growth for the latest annual reported period is not available.
- −Earnings per share (EPS) for the most recent financial year (Mar 2026) is not available.
- −Quarterly EPS figures are not available for any of the reported periods.
- −There is a decline in promoter shareholding from 82.84% in June 2022 to 74.87% in June 2026.
- −The number of shareholders has decreased from 233,538 in June 2022 to 125,559 in June 2026.
Business
Alivus Life Sciences Ltd. specializes in active pharmaceutical ingredients (APIs) for areas including cardiovascular disease, CNS disorders, diabetes, gastrointestinal health, oncology, and pain management. The company exports its products and also offers contract development and manufacturing services. Key APIs include olmesartan, telmisartan, sitagliptin, and rosuvastatin.
Financial Performance
In the financial year ending March 2026, Alivus Life Sciences Ltd. reported revenue of Rs 2551.83 Cr and a net profit of Rs 564.48 Cr. Quarterly revenue for March 2026 was Rs 689.12 Cr, with a net profit of Rs 162.66 Cr. The company's profit margin stands at 22.12%.
Profitability & Returns
The company's Return on Equity (ROE) is 16.94%, and Return on Capital Employed (ROCE) is 22.33%. Earnings per share (EPS) for the financial year ending March 2025 were Rs 39.52. The current P/E ratio is 24.08, and the dividend yield is 44%.
Balance Sheet
Alivus Life Sciences Ltd. has a book value of Rs 271.48. The debt-to-equity ratio is 0.01, indicating a low level of debt. The company does not have any promoter shares pledged, as per the latest available data.
Ownership & Pledges
The public shareholding is 12.41%. There are no shares pledged by the promoters.
Data as of — price: 2026-09-11 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.